Advertisement
Advertisement
Rezolute reports Q1 EPS (18c), consensus (26c)
PremiumThe FlyRezolute reports Q1 EPS (18c), consensus (26c)
8d ago
RZLT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
RZLT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
10d ago
Promising Potential of Rezolute’s Lead Candidate Ersodetug in Addressing Unmet Medical Need in cHI
Premium
Ratings
Promising Potential of Rezolute’s Lead Candidate Ersodetug in Addressing Unmet Medical Need in cHI
15d ago
Rezolute price target raised to $20 from $15 at Maxim
PremiumThe FlyRezolute price target raised to $20 from $15 at Maxim
2M ago
Rezolute price target raised to $20 from $15 at Maxim
Premium
The Fly
Rezolute price target raised to $20 from $15 at Maxim
2M ago
Rezolute’s Promising Progress and Financial Strength Justify Buy Rating
Premium
Ratings
Rezolute’s Promising Progress and Financial Strength Justify Buy Rating
2M ago
Rezolute’s Promising Future: FDA Approval and Strategic Valuation Drive Buy Rating
PremiumRatingsRezolute’s Promising Future: FDA Approval and Strategic Valuation Drive Buy Rating
2M ago
Rezolute’s Ersodetug Gains Momentum with FDA Support and Increased Success Probability, Raising Price Target
Premium
Ratings
Rezolute’s Ersodetug Gains Momentum with FDA Support and Increased Success Probability, Raising Price Target
2M ago
Rezolute’s Ersodetug Gains Momentum with FDA Streamlined Phase 3 Design and Promising Efficacy in Tumor-Induced Hyperinsulinism
Premium
Ratings
Rezolute’s Ersodetug Gains Momentum with FDA Streamlined Phase 3 Design and Promising Efficacy in Tumor-Induced Hyperinsulinism
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100